Education
About Us
Working with TipRanks
Follow Us
Rhythm Biosciences Ltd. (AU:RHY)
ASX:RHY
RHY Stock Chart & Stats
AU$0.14
<AU$0.01(1.16%)
At close: 4:00 PM EST
AU$0.14
<AU$0.01(1.16%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.28
Previous CloseN/A
Volume786.78K
Average Volume (3M)462.98K
Market Cap
AU$72.52M
Enterprise ValueAU$65.68M
Total Cash (Recent Filing)AU$1.73M
Total Debt (Recent Filing)AU$262.44K
Price to Earnings (P/E)―
Beta0.93
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding337,305,330
10 Day Avg. Volume510,821
30 Day Avg. Volume462,976
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)22.03
Price to Sales (P/S)4.56
P/FCF Ratio-4.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Product Pipeline (Colostat)Colostat targets population colorectal screening, a large, recurring addressable market. A validated blood-based alternative to invasive screening can drive durable adoption in clinical pathways, creating scalable, recurring revenues and strategic partnerships if clinical/market access progress continues.
High Gross Profit MarginA high gross margin implies attractive unit economics for the core diagnostic test. If revenue growth resumes, fixed costs and R&D amortization can be absorbed, enabling sustainable operating margin improvement and long-term profitability leverage.
Improving Free Cash Flow TrendsImproving free cash flow trends reduce near-term financing pressure and extend runway. Even with negative operating cash flow, better FCF conversion lowers dilution risk and supports continued clinical/commercial investment over the next several months if the trend persists.
Bears Say
Sharp Revenue DeclineA 42.87% revenue drop signals weak market traction or execution issues. Sustained revenue contraction undermines scale economics, delays breakeven, and makes it harder to fund commercialization and trials without additional financing or a clear revenue recovery catalyst.
Persistent Negative MarginsOngoing negative EBIT/EBITDA and net margins indicate the business is not generating operating profits from its core activities. This structural loss profile increases reliance on external funding and constrains investment in scaling commercial operations over the medium term.
Elevated Leverage And Weak ReturnsA debt-to-equity of 1.68 and negative ROE materially reduce financial flexibility. Debt servicing limits available cash for R&D and commercialization, and refinancing risk rises if cash flows remain negative, constraining strategic options over the next several months.
Rhythm Biosciences Ltd. News
RHY FAQ
What was Rhythm Biosciences Ltd.’s price range in the past 12 months?
Rhythm Biosciences Ltd. lowest share price was AU$0.05 and its highest was AU$0.28 in the past 12 months.
What is Rhythm Biosciences Ltd.’s market cap?
Rhythm Biosciences Ltd.’s market cap is AU$72.52M.
When is Rhythm Biosciences Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Rhythm Biosciences Ltd.’s earnings last quarter?
Currently, no data Available
Is Rhythm Biosciences Ltd. overvalued?
According to Wall Street analysts Rhythm Biosciences Ltd.’s price is currently Overvalued.
Does Rhythm Biosciences Ltd. pay dividends?
Rhythm Biosciences Ltd. does not currently pay dividends.
What is Rhythm Biosciences Ltd.’s EPS estimate?
Rhythm Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rhythm Biosciences Ltd. have?
Rhythm Biosciences Ltd. has 337,305,330 shares outstanding.
What happened to Rhythm Biosciences Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rhythm Biosciences Ltd.?
Currently, no hedge funds are holding shares in AU:RHY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rhythm Biosciences Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:RHY Sentiment 66%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$34.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.00%
12-Months-Change
Fundamentals
Return on Equity
-501.54%
Trailing 12-Months
Asset Growth
86.46%
Trailing 12-Months
Company Description
Rhythm Biosciences Ltd.
Rhythm Biosciences Limited, a transformative predictive cancer diagnostics technology company in Australia and internationally. The company engages in developing and commercializing medical diagnostics technology. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquartered in Parkville, Australia.
Technical Analysis
Genetic Technologies
―
BCAL Diagnostics Limited
―
Lumos Diagnostics Holdings Ltd.
―
Genetic Signatures Ltd.
―
Inoviq Ltd
―